AI-powered drug discovery and biodefence company Lunai Bioworks (NASDAQ:LNAI) announced on Monday that it has launched a new oncology collaboration with a clinical-stage partner to evaluate data from a randomised Phase 2 metastatic colorectal cancer trial.

The aim is to define biological patient subgroups that are likely to benefit most from the investigational therapy.

Under the pilot agreement, Lunai will deploy its proprietary Augusta AI platform to assess de-identified patient-level clinical, imaging, and longitudinal outcomes data, with a focus on overall survival and disease progression endpoints.

Lunai said that by integrating traditional clinical variables with AI-derived imaging features and temporal response patterns, the company aims to generate data-driven enrichment strategies designed to aid in the FDA trial design, including optimised inclusion criteria, endpoint strategy, and its statistical powering.

The collaboration is starting as a defined pilot project, with potential to expand into a broader commercial multi-study programme as supported by the data. If successful, the partners anticipate exploring additional applications across multiple tumour types, earlier-line treatment settings, and adaptive trial designs such as basket or umbrella studies.